항생제 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The antibiotics market size reached USD 55.60 billion in 2025 and is forecast to climb to USD 67.88 billion by 2030, yielding a compound annual growth rate (CAGR) of 4.07%.

This trajectory reflects a tug-of-war between the surge in antimicrobial resistance (AMR) and the steady expansion of healthcare coverage in large emerging economies. Investment in hospital capacity, tighter infection-control protocols, and new government incentives for innovative therapies are lifting demand, yet every driver also exposes stewardship gaps that restrain revenue growth. The antibiotics industry, therefore, operates between therapeutic necessity and responsible use, a balance that is slowly reshaping product pipelines toward targeted, microbiome-sparing drugs. Growing evidence from hospital buyers shows that pricing power remains strongest for newer agents with proven activity against difficult pathogens, a sign that payers will reward clear clinical differentiation. One fresh inference is that revenue momentum increasingly hinges on the ability to demonstrate both efficacy and stewardship value in the same product dossier.

Global Antibiotics Market Trends and Insights

Escalating Antimicrobial Resistance Necessitates Continuous Innovation

AMR already contributes to an estimated 4.95 million deaths each year and could reach 10 million by 2050 if left unchecked, as per the WHO in August 2024. This mounting toll is steering public and private capital toward first-in-class molecules, yet pipeline analysis shows that only 12 of 32 late-stage antibiotics introduce genuinely new mechanisms of action. Surveillance laboratories report that carbapenem-resistant Acinetobacter baumannii is appearing in community settings, forcing health ministries to fast-track funding for alternative treatments. Venture-funding trends reveal that investors increasingly favor platforms capable of delivering combination regimens, an approach that offers flexibility against evolving resistance patterns. A fresh inference is that investment appetites now track closely with a candidate's ability to address multiple high-priority pathogens rather than single-target designs.

Rising Incidence of Hospital-Acquired Infections in Tertiary-Care Settings

Roughly 3.8 million Europeans contract hospital-acquired infections (HAIs) annually, and 90,000 deaths are linked to these events, according to OECD, November 2024. Inpatient stays jump from seven to nineteen days when an HAI occurs, inflating opportunity costs past EUR 1,000 (USD 1,120) per case. Hospitals in low- and middle-income countries report even higher incidence, especially in intensive-care units where invasive procedures are standard and staffing ratios are lower. Financial modeling shows infection-control budgets are rising faster than overall hospital spending, indicating administrators now view HAI reduction as a core cost-containment lever. A new observation is that procurement departments increasingly specify antibiotics with smaller resistance footprints, signaling that stewardship metrics are becoming as important as acquisition price.

Rapid Proliferation of Multidrug-Resistant Pathogens

Hypervirulent Klebsiella pneumoniae strains carrying carbapenem-resistance genes emerged during 2024, according to the WHO in July 2024, raising new concerns for neonatal and intensive-care wards. Surveillance across India and sub-Saharan Africa shows sharp rises in cephalosporin and fluoroquinolone resistance, patterns now cropping up in community clinics as well. Each new resistance cluster compresses the commercial life of established drugs and prompts clinicians to escalate therapy earlier, elevating treatment costs. An emerging observation is that reimbursement agencies are beginning to weigh resistance modeling when negotiating antibiotic prices, effectively linking payment levels to predicted durability.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Universal Health Coverage Enhances Essential Antibiotics Access
2. Technological Advancements in B-lactamase Inhibitor Combinations
3. Stringent Stewardship Policies Limit Use of "Watch" and "Reserve" Classes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cephalosporins command 24.2% antibiotics market share in 2025, translating to a market size of USD 13.49 billion. Their broad pathogen coverage and inclusion in multiple clinical guidelines sustain demand. The U.S. approval of Zevtera for three indications, including Staphylococcus aureus bloodstream infections, bolsters prescriber trust. Stewardship teams now pair cephalosporins with rapid diagnostics to shorten empiric-therapy windows, a workflow change that can curb resistance without denting unit sales. One fresh inference is that coupling diagnostics with established drugs extends their relevance even in resistance-heavy settings.

Carbapenems reveal the strongest forecast CAGR of 6.8% through 2030, underscoring their status as last-line agents for multidrug-resistant infections. Utilization audits show clinicians increasingly reserve carbapenems for culture-confirmed cases, a practice that can stabilize resistance trends. Manufacturers support demand by launching once-daily formulations suitable for outpatient parenteral-antibiotic therapy. Evidence from infectious-disease pharmacists indicates stewardship committees approve carbapenem requests more readily when bolstered by local antibiograms, implying steady growth even under usage constraints.

The Antibiotics Market is Segmented by Product Type (Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, and Other Product Types), Spectrum (Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Geography Analysis

Asia-Pacific held 34.27% antibiotics market share in 2025, worth USD 19.05 billion, and is projected to post a 7.2% CAGR through 2030. The region's large population, high infection burden, and widening insurance coverage underpin this dominance. Governments such as Indonesia paired national AMR plans with local manufacturing incentives in 2024, stimulating both supply security and quality improvements. China and India serve as global production hubs for generics while investing aggressively in novel candidates, an approach that positions domestic firms to ascend the value chain. Japan's sophisticated stewardship policies demonstrate that mature markets can curb overuse without harming access, offering a blueprint for peers. A new observation is that public health agencies in the region now deploy cloud-based surveillance dashboards, accelerating response times to emerging resistance clusters.

North America ranks second in market size and sets regulatory and pricing benchmarks. The U.S. Generating Antibiotic Incentives Now (GAIN) Act extends exclusivity for qualified infectious-disease products, a tool that aided approvals such as EXBLIFEP and ORLYNVAH. Insurers reimburse these therapies at premium rates when resistance documentation accompanies claims, indicating payers see value beyond acquisition price. Canada's coordinated surveillance network supplies granular resistance data, letting hospitals refine empiric protocols and reduce unnecessary broad-spectrum use. An emergent inference is that markets with robust surveillance can both limit misuse and still reward innovation through targeted reimbursement.

Europe maintains a solid third position, led by Germany, the United Kingdom and France. The European Medicines Agency's streamlined routes for unmet-need antibiotics shorten filing timelines, encouraging companies to launch first in the bloc. Public-procurement frameworks move toward outcome-based contracts, rewarding suppliers for demonstrable clinical and stewardship benefits rather than lowest unit cost alone. Meanwhile, the Middle East, albeit smaller, posts the fastest regional CAGR of 7.2% as Gulf states upgrade tertiary infrastructure and adopt Western infection-control standards. Hospitals in the United Arab Emirates increasingly demand advanced carbapenem and BLI combinations, a sign the region is leapfrogging intermediate therapies. A fresh inference is that diversified procurement budgets in energy-rich Gulf economies can accelerate adoption of premium antibiotics faster than population size alone would predict.

1. Johnson & Johnson
2. Merck
3. Pfizer
4. Bayer
5. Novartis
6. Abbott Laboratories
7. Otsuka
8. Eli Lilly and Company
9. GlaxoSmithKline
10. Sanofi
11. Teva Pharmaceutical Industries
12. Lupin
13. Sun Pharmaceuticals Industries
14. Cipla
15. Viatris
16. Hikma Pharmaceuticals
17. Shionogi & Co., Ltd.
18. Melinta Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Antimicrobial Resistance (AMR) Worldwide Necessitating Continuous Antibiotic Innovation and Stockpiling
  • 4.2.2 Rising Incidence of Hospital-Acquired Infections in Tertiary-Care Settings Across Emerging Economies
  • 4.2.3 Expansion of Universal Health Coverage and Public Reimbursement for Essential Antibiotics in High-Burden Regions
  • 4.2.4 Technological Advancements in Beta-lactamase Inhibitor Combinations and Novel Modalities Enhancing Treatment Outcomes
  • 4.2.5 Growing Focus on Pandemic Preparedness and Strategic National Antibiotic Reserves
  • 4.2.6 Government-funded Antibiotic Stewardship Programs Mandating Reserve Antibiotic Stockpiling and Procurement
• 4.3 Market Restraints
  • 4.3.1 Rapid Proliferation of Multidrug-Resistant Pathogens Outpacing Commercial Development Timelines
  • 4.3.2 Stringent Stewardship and Procurement Policies Limiting Use of "Watch" and "Reserve" Classes
  • 4.3.3 High Clinical-Trial Failure Rates and Unfavorable Return on Investment Deterring Private R&D Funding
  • 4.3.4 Disruptions in Active Pharmaceutical Ingredient (API) Supply Chains Concentrated in Few Manufacturing Hubs
• 4.4 Value Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product Type
  • 5.1.1 Cephalosporins
  • 5.1.2 Penicillins
  • 5.1.3 Fluoroquinolones
  • 5.1.4 Macrolides
  • 5.1.5 Carbapenems
  • 5.1.6 Aminoglycosides
  • 5.1.7 Sulfonamides
  • 5.1.8 Other Product Types
• 5.2 By Spectrum
  • 5.2.1 Broad-spectrum Antibiotics
  • 5.2.2 Narrow-spectrum Antibiotics
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 South Korea
    • 5.3.3.5 Australia
    • 5.3.3.6 Rest of Asia
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Johnson & Johnson
  • 6.3.2 Merck & Co., Inc.
  • 6.3.3 Pfizer Inc.
  • 6.3.4 Bayer AG
  • 6.3.5 Novartis AG (Sandoz)
  • 6.3.6 Abbott Laboratories
  • 6.3.7 Otsuka Pharmaceutical Co., Ltd.
  • 6.3.8 Eli Lilly and Company
  • 6.3.9 GlaxoSmithKline plc
  • 6.3.10 Sanofi
  • 6.3.11 Teva Pharmaceutical Industries Ltd.
  • 6.3.12 Lupin Limited
  • 6.3.13 Sun Pharmaceutical Industries Ltd.
  • 6.3.14 Cipla Ltd.
  • 6.3.15 Viatris Inc. (Mylan)
  • 6.3.16 Hikma Pharmaceuticals PLC
  • 6.3.17 Shionogi & Co., Ltd.
  • 6.3.18 Melinta Therapeutics

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment